On January 12, Eli Lilly announced a five-year, up to $1 billion partnership with Nvidia to establish an AI innovation lab in the San Francisco Bay Area. The facility will bring together Eli Lilly’s medicinal chemists, biologists and clinical researchers with Nvidia’s AI engineers to co-develop machine-learning models aimed at reducing the time and cost of early-stage drug discovery. This initiative builds on Eli Lilly’s October announcement of an industry-leading supercomputer, also developed with Nvidia technology, and the 2023 launch of TuneLab, a free AI-driven drug-discovery platform provided to smaller biotech firms to expand the company’s data pool for model training.

Eli Lilly’s tirzepatide, marketed for weight management under the brand name Zepbound, emerged as the world’s top-selling pharmaceutical product in the third quarter of 2025. Strong global uptake drove company-wide revenue growth of 54% year-over-year to $17.6 billion in Q3, while adjusted earnings per share reached $6.21, representing a 480% increase compared with the same period in 2024. Management forecasts Zepbound will remain a multibillion-dollar revenue engine through 2030, underpinning the company’s top-line expansion and offsetting pricing pressures in other therapeutic areas.

The U.S. Food and Drug Administration has postponed its ruling on Eli Lilly’s investigational oral obesity therapy, orforglipron, extending the target decision date from February to April 2026. The delay follows additional data requests regarding long-term safety endpoints and patient adherence metrics. While this pushes potential U.S. market entry into the second quarter, analysts note that successful approval would position Eli Lilly to capture a significant share of the emerging oral obesity market, estimated at $25 billion by 2030, and complement its injectable weight-management portfolio.